Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Microlin Bio Inc.
NEW YORK, Jan. 10, 2014 /PRNewswire/ -- Microlin Bio, Inc., a development stage biotechnology company focused primarily on the development of microRNA based therapeutics and diagnostics to treat cancer from technologies licensed from the Ohio State University, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a $25,000,000 proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Microlin Bio.
Sunrise Securities Corp. is acting as sole book-running manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Sunrise Securities Corp., Attention: Marcia Kucher, 600 Lexington Avenue, 23rd Floor, New York, NY 10022, Telephone: (212) 421-1616 E-mail: firstname.lastname@example.org.
About Microlin Bio, Inc.
Microlin Bio is a development stage biotechnology company focused primarily on the development of microRNA based therapeutics and diagnostics to treat cancer from technologies licensed from the Ohio State University.
For more information about Microlin Bio, please contact Danielle Spangler of Microlin Bio, Inc. at email@example.com or at 646-612-4000.
©2012 PR Newswire. All Rights Reserved.